Boston Scientific is adding to its medsurg portfolio by acquiring a controlling interest in MI Tech, a Korean company that markets the Hanarostent line of nitinol stents for a variety of non-vascular indications.
On 15 June, Boston Scientific announced that it has reached a definitive agreement with Synergy Innovation Co to purchase its stake in MI Tech – approximately 64% of the company – for 14,500